Clinical Trials Logo

Neuralgia clinical trials

View clinical trials related to Neuralgia.

Filter by:

NCT ID: NCT00407511 Completed - Clinical trials for Chemotherapy Induced Neuropathic Pain

Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP

Start date: January 2007
Phase: Phase 4
Study type: Interventional

Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.

NCT ID: NCT00394901 Completed - Clinical trials for Neuralgia, Postherpetic

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

NCT ID: NCT00391079 Completed - Multiple Sclerosis Clinical Trials

Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple sclerosis. This type of pain "central neuropathic pain" is described as shooting, stabbing, burning or searing like sensation, which is often worse at night.

NCT ID: NCT00390845 Completed - Pain, Neuropathic Clinical Trials

P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

Start date: August 30, 2006
Phase: Phase 2
Study type: Interventional

This will be a double-blind, placebo controlled cross-over study. After enrolment and initial assessments, subjects will receive oral SB681323 or matching placebo for 14 days. SB681323 will be administered twice daily at a total daily dose of 7.5mg. Sufficient numbers of patients will be recruited to obtain 40 evaluable patients

NCT ID: NCT00385671 Completed - Clinical trials for Diabetic Neuropathy, Painful

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

Start date: September 2006
Phase: Phase 4
Study type: Interventional

To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.

NCT ID: NCT00377598 Completed - Clinical trials for Neuralgia, Postherpetic

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Start date: October 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of TAK-583, once daily (QD), in relieving pain in subjects with postherpetic neuralgia.

NCT ID: NCT00376454 Completed - Neuropathic Pain Clinical Trials

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.

NCT ID: NCT00375960 Completed - Pain Clinical Trials

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and arms, sometimes experienced by people with diabetes). An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) and/or Health Canada.

NCT ID: NCT00350532 Completed - Pain Clinical Trials

Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the amount of acetylcholine release after a single injection of clonidine in normal volunteers and individuals with neuropathic pain.

NCT ID: NCT00349921 Completed - Pain Clinical Trials

Clonidine Versus Adenosine to Treat Neuropathic Pain

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.